Literature DB >> 29434958

Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways.

Xiong Min1, Han Heng1, Hua-Long Yu1, Mao Dan1, Chen Jie1, Yun Zeng1, He Ning1, Zhi-Gang Liu1, Zhi-Yong Wang1, Wang Lin1.   

Abstract

In order to evaluate the anticancer effect of 10-hydroxycamptothecin (HCPT) in terms of inducing the apoptosis of human osteosarcoma cells, its apoptosis-inducing molecular mechanisms were investigated. In the present study, the anticancer effects of HCPT were revealed to result in suppressed cell viability, increased cytotoxicity, the induction of apoptosis and an augmented apoptotic nucleolus of human osteosarcoma cells. MG-63 cells were cultured with HCPT (0, 20, 40 and 80 nM) for 24 and 48 h. An MTT assay and a lactate dehydrogenase assay were used to analyze the anticancer effect of HCPT on cell viability and cytotoxicity in MG-63 cells. MG-63 cell apoptosis, and caspase-9 and caspase-3 activity levels were evaluated using flow cytometry and an ELISA. Western blot analysis was used to detect the protein expression levels of p53, poly (ADP-ribose) polymerase-1 (PARP-1), cytochrome c and B cell lymphoma-2 (Bcl-2) in MG-63 cells. The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. In conclusion, the anticancer effects of HCPT appear to induce the apoptosis of human osteosarcoma cells through the activation of the caspase-3, p53 and cytochrome c pathways.

Entities:  

Keywords:  10-hydroxycamptothecin; caspase-3; cytochrome c pathway; osteosarcoma; p53

Year:  2017        PMID: 29434958      PMCID: PMC5777291          DOI: 10.3892/ol.2017.7610

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  Anticancer properties of 10-hydroxycamptothecin in a murine melanoma pulmonary metastasis model in vitro and in vivo.

Authors:  Wei Hu; Chao Zhang; Yun Fang; Chenghua Lou
Journal:  Toxicol In Vitro       Date:  2010-11-18       Impact factor: 3.500

2.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark Krailo; Eugenie S Kleinerman; Donna Betcher; Mark L Bernstein; Ernest Conrad; William Ferguson; Mark Gebhardt; Allen M Goorin; Michael B Harris; John Healey; Andrew Huvos; Michael Link; Joseph Montebello; Helen Nadel; Michael Nieder; Judith Sato; Gene Siegal; Michael Weiner; Robert Wells; Lester Wold; Richard Womer; Holcombe Grier
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

3.  Lipid nanoparticles loaded with 10-hydroxycamptothecin-phospholipid complex developed for the treatment of hepatoma in clinical application.

Authors:  Wei Wei; San-Jun Shi; Jie Liu; Xun Sun; Ke Ren; Dong Zhao; Xiao-Ning Zhang; Zhi-Rong Zhang; Tao Gong
Journal:  J Drug Target       Date:  2010-08       Impact factor: 5.121

4.  Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain.

Authors:  T M Fan; S C Charney; L P de Lorimier; L D Garrett; D J Griffon; W J Gordon-Evans; J M Wypij
Journal:  J Vet Intern Med       Date:  2009 Jan-Feb       Impact factor: 3.333

5.  PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer.

Authors:  Xinxin Zhang; Yong Gan; Li Gan; Shufang Nie; Weisan Pan
Journal:  J Pharm Pharmacol       Date:  2008-08       Impact factor: 3.765

6.  SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.

Authors:  Sílvia Carvalho; Alexandra C Vítor; Sreerama C Sridhara; Filipa B Martins; Ana C Raposo; Joana M P Desterro; João Ferreira; Sérgio F de Almeida
Journal:  Elife       Date:  2014-05-06       Impact factor: 8.140

7.  Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis.

Authors:  Jinmin Zhao; Hua Xu; Maolin He; Zhe Wang; Yang Wu
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

8.  PARP1 gene expression is downregulated by knockdown of PARG gene.

Authors:  Fumiaki Uchiumi; Takeshi Watanabe; Ryo Ohta; Hideaki Abe; Sei-Ichi Tanuma
Journal:  Oncol Rep       Date:  2013-03-04       Impact factor: 3.906

9.  Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells.

Authors:  Sujoy Dutta; Case Warshall; Chirosree Bandyopadhyay; Dipanjan Dutta; Bala Chandran
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

10.  Survivin contributes to DNA repair by homologous recombination in breast cancer cells.

Authors:  Eloïse Véquaud; Grégoire Desplanques; Pascal Jézéquel; Philippe Juin; Sophie Barillé-Nion
Journal:  Breast Cancer Res Treat       Date:  2015-12-18       Impact factor: 4.872

View more
  6 in total

1.  CircRNA LRP6 promotes the development of osteosarcoma via negatively regulating KLF2 and APC levels.

Authors:  Shengnai Zheng; Zhanyang Qian; Fan Jiang; Dawei Ge; Jian Tang; Hongtao Chen; Jin Yang; Yilun Yao; Junwei Yan; Lei Zhao; Haijun Li; Lei Yang
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

2.  Comparative Study of Antiproliferative Activity in Different Plant Parts of Phaleria macrocarpa and the Underlying Mechanism of Action.

Authors:  Yuyun Ika Christina; Muhaimin Rifa'i; Nashi Widodo; Muhammad Sasmito Djati
Journal:  ScientificWorldJournal       Date:  2022-06-13

3.  Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.

Authors:  Chun-Hui Wang; Jia-Min Yang; Yu-Bo Guo; Jing Shen; Xiao-Hua Pei
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-30       Impact factor: 2.629

4.  3,4‑Dihydroxyacetophenone attenuates oxidative stress‑induced damage to HUVECs via regulation of the Nrf2/HO‑1 pathway.

Authors:  Daihong Cao; Yunhan Wang; Wentao Li; Jiafen Ji; Juntang Guo; Daijuan Zhang; Jiangyue Liu
Journal:  Mol Med Rep       Date:  2022-04-27       Impact factor: 3.423

5.  Construction of a circRNA-miRNA-mRNA network based on competitive endogenous RNA reveals the function of circRNAs in osteosarcoma.

Authors:  Yu Qiu; Chao Pu; Yanchao Li; Baochuang Qi
Journal:  Cancer Cell Int       Date:  2020-02-10       Impact factor: 5.722

Review 6.  Clinical Potential of Fruit in Bladder Cancer Prevention and Treatment.

Authors:  Paulina Wigner; Michał Bijak; Joanna Saluk-Bijak
Journal:  Nutrients       Date:  2022-03-08       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.